We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Noninvasive Procedure Improves Success Rate of IVF

By LabMedica International staff writers
Posted on 19 Nov 2008
A safe, simple, noninvasive procedure provides an objective measure of embryo viability, and when used as an adjunct to morphology, helps clinicians identify embryos of highest reproductive potential for in vitro fertilization (IVF). More...


Called the ViaMetrics-E procedure, it uses a highly sensitive method of metabolomic analysis by near infrared (NIR) spectroscopy, the can be performed on-site in just minutes, requiring only a small amount of spent culture media.

The procedure promises to be revolutionary for the millions of people worldwide who are affected by infertility. The technology fulfills an unmet medical need and it is well positioned to tap into the US$4 billion global IVF market. Further, the technology may hold significant potential to increase IVF success rates, while minimizing the number IVF cycles required to achieve a live birth. ViaMetrics-E could also provide physicians with a procedure that will reduce the incidence, costs, and medical risks associated with multiple births, which constitute more than one-third of births under current IVF methods.

ViaMetrics-E was developed by the metabolomics company, Molecular Biometrics (Chester, NJ, USA). Safeguard Scientifics (Wayne, PA, USA), a holding company that provides growth capital for entrepreneurial and innovative technology and life sciences companies, has announced it co-led a $12 million Series A financing round with Oxford Bioscience Partners (OBP; Boston, MA, USA), a venture capital firm, for Molecular Biometrics. Molecular Biometrics will use the financing to support ongoing R&D for ViaMetrics-E and to launch the patented technology in Europe, Japan, and Australia sometime in 2009.

James A. Datin, executive vice president and managing director of the Life Sciences Group at Safeguard commented, "Safeguard partners with entrepreneurial life sciences companies who have differentiated products and a competitive advantage in markets that represent sizable opportunities. We look for strong management teams that address key strategic themes throughout our target markets--molecular and point-of-care diagnostics, medical devices or specialty pharmaceuticals--and are on a solid trajectory towards global commercialization.”

Related Links:
Molecular Biometrics
Safeguard Scientifics
Oxford Bioscience Partners


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Immunofluorescence Analyzer
IFA System
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.